The efficacy of the combination drug of hydroxymethylquinoxalinedioxide + isoniazid lyophilisate in the treatment of bronchial tuberculosis
https://doi.org/10.21292/2075-1230-2019-97-4-30-34
Abstract
The objective of the study: to evaluate the safety and efficacy of the combination drug of hydroxymethylquinoxalinedioxide + isoniazid lyophilisate within chemotherapy of patients with bronchial tuberculosis complicating pulmonary tuberculosis.
Subjects and methods. Adverse effects of the combination drug were studied in 26 patients with bronchial and pulmonary tuberculosis who had inhalations with hydroxymethylquinoxalinedioxide + isoniazid lyophilisate.
The treatment efficacy of bronchial tuberculosis was compared in Group I (24 patients who received basic therapy for tuberculosis and inhalation) versus Group II (34 patients who received basic therapy only).
Results. Adverse events occurred in 4/26 patients (15.4%, 95% CI 5.5-34.2%) who had inhalations with a solution of hydroxymethylquinoxalinedioxide + isoniazid lyophilisate due to bronchial tuberculosis, 2/26 (7.7 % 95% CI 1.0-25.3%) had to have the drug discontinued.
Treatment efficacy of bronchial tuberculosis was statistically significantly higher in patients from Group I (based on endoscopy data) compared to Group II (after 1 month of treatment, 20/24 (83.3%) and 14/34 (41.2%), respectively; p = 0.001 Fischer’s Exact test; after 6 months 23/24 (95.8%) and 26/34 (76.5%), respectively; p = 0.041 Fischer’s Exact test).
About the Author
A. A. Stаrshinovа
St. Petersburg Research Institute of Phthisiopulmonology
Russian Federation
Russian Federation
Anna A. Starshinova - Doctor of Medical Sciences, Leading Researcher.
2-4, Ligovsky Ave., St. Petersburg, 191036, Phone/Fax: +7 (812) 297-22-63; +7 (812) 297-16-26
References
1. Glushkov M.I. et al. Kombinirovannye protivotuberkuleznye lekarstvennye sredstva, predstavlyayuschie soboy kompozitsiyu proizvodnykh khinoksalin-1,4-dioksida s izvestnymi protivotuberkuleznymi preparatami. [Combination anti-tuberculosis drugs consisting of quinoxalin-1,4-dioxide with known anti-tuberculosis drugs]. RF Patent no. 2209067, published as of 27.07.2003, Bull. no. 21.
2. Glushkov R.G. et al. New approaches to chemotherapy of tuberculosis. The original combination anti-tuberculosis drug of Dioxazid. Probl. Tub., 2007, no. 3, pp. 20-25. (In Russ.)
3. Glushkov R.G., Sokolova G.B. The new combination anti-tuberculosis drug of Khixozid. Antibiotiki i Khimioterapiya, 2008, no. 5-6, pp. 11-13. (In Russ.)
4. Kiryanova V.V., Levashov А.N. Physiotherapy for respiratory tuberculosis patients Fizioterapiya, Balneologiya i Reabilitatsiya, 2010, no. 1, pp. 37-48. (In Russ.)
5. Logunova I.V., Bogomolova N.S., Chistyakov V.V. Experimental study of bioavailability of the combination drug of Dioxazid. Farmakokinetika i Farmakodinamika, 2012, no. 1, pp. 29-32. (In Russ.)
6. Federalnye klinicheskie rekomendatsii po diagnostike i lecheniyu tuberkuleza organov dykhaniya. [Federal recommendations for diagnostics and treatment of respiratory tuberculosis]. Moscow, Triada Publ., 2014. pp. 55.
Review
For citations:
Stаrshinovа A.A. The efficacy of the combination drug of hydroxymethylquinoxalinedioxide + isoniazid lyophilisate in the treatment of bronchial tuberculosis. Tuberculosis and Lung Diseases. 2019;97(4):30-34. (In Russ.) https://doi.org/10.21292/2075-1230-2019-97-4-30-34
Views:
1203
Email this article 